126 related articles for article (PubMed ID: 36966904)
1. Insulin dysregulation drives mitochondrial cholesterol metabolite accumulation: initiating hepatic toxicity in nonalcoholic fatty liver disease.
Minowa K; Rodriguez-Agudo D; Suzuki M; Muto Y; Hirai S; Wang Y; Su L; Zhou H; Chen Q; Lesnefsky EJ; Mitamura K; Ikegawa S; Takei H; Nittono H; Fuchs M; Pandak WM; Kakiyama G
J Lipid Res; 2023 May; 64(5):100363. PubMed ID: 36966904
[TBL] [Abstract][Full Text] [Related]
2. Coffee modulates insulin-hepatocyte nuclear factor-4α-Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a nonalcoholic fatty liver disease mouse model.
Kakiyama G; Minowa K; Rodriguez-Agudo D; Martin R; Takei H; Mitamura K; Ikegawa S; Suzuki M; Nittono H; Fuchs M; Heuman DM; Zhou H; Pandak WM
Am J Physiol Gastrointest Liver Physiol; 2022 Nov; 323(5):G488-G500. PubMed ID: 36193897
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Cholesterol Metabolites in a Bile Acid Synthetic Pathway Drive Nonalcoholic Fatty Liver Disease: A Revised "Two-Hit" Hypothesis.
Kakiyama G; Rodriguez-Agudo D; Pandak WM
Cells; 2023 May; 12(10):. PubMed ID: 37408268
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols.
Kakiyama G; Marques D; Takei H; Nittono H; Erickson S; Fuchs M; Rodriguez-Agudo D; Gil G; Hylemon PB; Zhou H; Bajaj JS; Pandak WM
J Steroid Biochem Mol Biol; 2019 May; 189():36-47. PubMed ID: 30710743
[TBL] [Abstract][Full Text] [Related]
5. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition.
Kakiyama G; Marques D; Martin R; Takei H; Rodriguez-Agudo D; LaSalle SA; Hashiguchi T; Liu X; Green R; Erickson S; Gil G; Fuchs M; Suzuki M; Murai T; Nittono H; Hylemon PB; Zhou H; Pandak WM
J Lipid Res; 2020 Dec; 61(12):1629-1644. PubMed ID: 33008924
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
8. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
9. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
Chun HJ; Shim YJ; Kwon YH
J Nutr Biochem; 2022 Feb; 100():108869. PubMed ID: 34563665
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.
Mukherjee S; Chakraborty M; Ulmasov B; McCommis K; Zhang J; Carpenter D; Msengi EN; Haubner J; Guo C; Pike DP; Ghoshal S; Ford DA; Neuschwander-Tetri BA; Chakraborty A
Mol Metab; 2021 Dec; 54():101364. PubMed ID: 34757046
[TBL] [Abstract][Full Text] [Related]
11. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
Xu L; Kim JK; Bai Q; Zhang X; Kakiyama G; Min HK; Sanyal AJ; Pandak WM; Ren S
Mol Pharmacol; 2013 Mar; 83(3):648-58. PubMed ID: 23258548
[TBL] [Abstract][Full Text] [Related]
12. Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease.
Korish AA; Arafah MM
BMC Complement Altern Med; 2013 Oct; 13():264. PubMed ID: 24119413
[TBL] [Abstract][Full Text] [Related]
13. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.
Van Rooyen DM; Larter CZ; Haigh WG; Yeh MM; Ioannou G; Kuver R; Lee SP; Teoh NC; Farrell GC
Gastroenterology; 2011 Oct; 141(4):1393-403, 1403.e1-5. PubMed ID: 21703998
[TBL] [Abstract][Full Text] [Related]
14. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
15. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
[TBL] [Abstract][Full Text] [Related]
16. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
17. Stigmasterol Protects Against Steatohepatitis Induced by High-Fat and High-Cholesterol Diet in Mice by Enhancing the Alternative Bile Acid Synthesis Pathway.
Xin Y; Li X; Zhu X; Lin X; Luo M; Xiao Y; Ruan Y; Guo H
J Nutr; 2023 Jul; 153(7):1903-1914. PubMed ID: 37269906
[TBL] [Abstract][Full Text] [Related]
18. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice.
Zheng N; Wang H; Zhu W; Li Y; Li H
J Ethnopharmacol; 2024 Feb; 320():117401. PubMed ID: 37967775
[TBL] [Abstract][Full Text] [Related]
19. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.
Henkel J; Coleman CD; Schraplau A; Jӧhrens K; Weber D; Castro JP; Hugo M; Schulz TJ; Krämer S; Schürmann A; Püschel GP
Mol Med; 2017 May; 23():70-82. PubMed ID: 28332698
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
